Atrial Fibrillation During Zanubrutinib Treatment in Chronic Lymphocytic Leukemia With a Historical Ibrutinib Control

ABSTRACT Introduction Atrial fibrillation (AF) complicates Bruton tyrosine kinase inhibitor therapy in chronic lymphocytic leukemia. Methods We retrospectively evaluated 679 zanubrutinib‐treated patients across 52 Italian centers, with 354 historical ibrutinib‐treated controls. Shanafelt AF scores were assessed. Results Nine zanubrutinib‐treated patients developed AF (1.33%) during median treatment of 15.5 months, versus 42 historical controls (11.9%) over median observation of 25 months. Five zanubrutinib events occurred among patients scoring ≥ 5. No affected patients experienced embolic or bleeding complications. Conclusion AF was uncommon during zanubrutinib treatment, even in the higher‐risk subgroup. Historical comparisons remain limited, and exploratory score findings require confirmation with longer follow‐up. Trial Registration The authors have confirmed clinical trial registration is not needed for this submission

Authors

Institutions

Publication Details

Journal
eJHaem
Published
2026-11-14
DOI
https://doi.org/10.1002/jha2.70451
Primary Topic
Chronic Lymphocytic Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Atrial Fibrillation During Zanubrutinib Treatment in Chronic Lymphocytic Leukemia With a Historical Ibrutinib Control

Enrico Derenzini, Ilaria Angeletti, Candida Vitale, Isacco Ferrarini et al.
eJHaem
Chronic Lymphocytic Leukemia Research
article

Atrial Fibrillation During Zanubrutinib Treatment in Chronic Lymphocytic Leukemia With a Historical Ibrutinib Control

Enrico Derenzini, Ilaria Angeletti, Candida Vitale, Isacco Ferrarini, Laura Nocilli, Alessandra Tedeschi, Alessandro Allegra, Giulio Giordano, Nicola Di Renzo, Enrica Antonia Martino, Livio Trentin, Vanessa Innao, Esmeralda Conte, Sara Pepe, Massimo Gentile, Massimiliano Postorino, Alessandro Maggi, Marina Motta, Giuseppe Pietrantuono, Francesca Romana Mauro, Alessandro Cellini, Barbara Pocali, Riccardo Moia, Salvatrice Mancuso, Marcello Riva, Pietro Bulian, Francesco Di Raimondo, Marta Coscia, Luana Schiattone, Annalisa Chiarenza, Antonella Bruzzese, Vittorio Del Fabro, Andrea Visentin, Arcangelo Liso, Idanna Innocenti, Laura Ballotta, Claudia Giordano, Annamaria Giordano, Stefania Scardino, Paola Anticoli Borza, Federico Vozella, Valentina Zammit, Lucia Morello, Giacomo Loseto, Luigi Malandruccolo, Anna Mele, Michele Merli, Luca Scalise, Piero Galieni, Angelo Famà, Francesco Malaspina, Nicola Amodio, Ilaria Scortechini, Fabio Stagno, Marzia Varettoni, Francesco Angotzi, Roberto Marasca, Paolo Sportoletti, Andrea Duminuco, Catello Califano, Daniele Caracciolo, P Musto, Ernesto Vigna, Adalberto Ibatici, Gioacchino Catania, Laura Caruso, Giuliana Farina, Martina Cantelli, Massimo Moratti, Andrea Ferrario, Giorgio Tona, Anna Maria Frustaci, Gianluca Gaidano, Amalia Figuera, Alessandro Sanna, Caterina Stelitano, Raffaella Pasquale, Giuseppe Alberto Palumbo, Roberta Murru, Valter Gattei, Elsa Pennese, Fortunato Morabito, Vincenzo Fraticelli, Annalisa Pitino, Giovanni Tripepi, Rosanna Miccolis, Azzurra Romeo, Luca Laurenti, Maria Ilaria Del Principe, Valentina Di Martina, Marco Rossi, Sara Galimberti, Paolo Fiumara
article en

Abstract

ABSTRACT Introduction Atrial fibrillation (AF) complicates Bruton tyrosine kinase inhibitor therapy in chronic lymphocytic leukemia. Methods We retrospectively evaluated 679 zanubrutinib‐treated patients across 52 Italian centers, with 354 historical ibrutinib‐treated controls. Shanafelt AF scores were assessed. Results Nine zanubrutinib‐treated patients developed AF (1.33%) during median treatment of 15.5 months, versus 42 historical controls (11.9%) over median observation of 25 months. Five zanubrutinib events occurred among patients scoring ≥ 5. No affected patients experienced embolic or bleeding complications. Conclusion AF was uncommon during zanubrutinib treatment, even in the higher‐risk subgroup. Historical comparisons remain limited, and exploratory score findings require confirmation with longer follow‐up. Trial Registration The authors have confirmed clinical trial registration is not needed for this submission

eJHaemVol. 7(6)
University of Pisa (IT), University of Messina (IT), University of Rome Tor Vergata (IT), University of Verona (IT), Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT), University of Padua (IT), Università degli Studi di Enna Kore (IT), University of Perugia (IT), Azienda Ospedaliera San Giovanni Addolorata (IT), Ospedale di Circolo e Fondazione Macchi (IT), Agostino Gemelli University Polyclinic (IT), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT), Magna Graecia University (IT), Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT), Ospedale Antonio Cardarelli (IT), Ospedale "Santa Maria delle Croci" di Ravenna (IT), Centro di Riferimento Oncologico della Basilicata (IT), Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT), Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari (IT), Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT), Azienda ospedaliera "Bianchi-Melacrino-Morelli" (IT), Azienda Ospedaliera di Cosenza (IT), Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT), Ospedale Garibaldi (IT), Istituto di Fisiologia Clinica (IT), Ospedale di Santo Spirito (IT), Azienda Ospedaliero Universitaria Ospedali Riuniti (IT), Azienda Ospedaliero-Universitaria di Modena (IT), Azienda Ospedaliera S.Giuseppe Moscati (IT), Azienda Ospedaliero-Universitaria Careggi (IT), Federico II University Hospital (IT), Azienda Ospedaliera Sant'Andrea (IT), Centro di Riferimento Oncologico (IT), Policlinico Universitario di Catania (IT), Istituto Tumori Bari (IT), Ospedale Annunziata di Cosenza (IT), Azienda Ospedaliero-Universitaria "Renato Dulbecco" (IT), Nini Hospital (LB), Guglielmo da Saliceto Hospital (IT), Ospedale Santa Maria Goretti (IT), St. Eugenio Hospital (IT), Campus Bio Medico University Hospital (IT), Ospedale Policlinico San Martino (IT), Ospedale Sant'Anna (IT), Policlinico San Matteo Fondazione (IT), Ospedale San Bortolo (IT), Ospedale Vito Fazzi (IT), National Research Council (IT), Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo (IT), La Maddalena (IT), Azienda Sanitaria Universitaria Integrata di Trieste (IT), Azienda Ospedaliera Universitaria Pisana (IT), Azienda Ospedaliera Ospedali Riuniti Papardo Piemonte (IT), Aziende Socio Sanitarie Territoriale dei Sette Laghi (IT), Azienda sanitaria universitaria Friuli Centrale (IT), Pia Fondazione di Culto e Religione Azienda Ospedaliera "Card. G. Panico" (IT), University of Calabria (IT), University of Turin (IT), University of Bari Aldo Moro (IT), European Institute of Oncology (IT), University of Naples Federico II (IT), Sapienza University of Rome (IT), University of Palermo (IT)
Chronic Lymphocytic Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon